Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
Level 3 - non-randomized controlled study
Non-randomized longitudinal cohort follow-up study
What was done
Researchers reanalyzed previously published longitudinal follow-up data comparing 140 individuals with ADHD to 120 controls. The analysis assessed whether naturalistic exposure to stimulant pharmacotherapy among youth with ADHD influenced subsequent rates of substance use disorders, including abuse and dependence.
What was found
Stimulant pharmacotherapy was associated with protection against substance use disorders. Individuals with untreated ADHD developed substance use disorders at rates 3 to 4 times higher than medicated ADHD patients. The abstract reports no exact percentages, hazard ratios, or confidence intervals.
Why it matters
It provides longitudinal evidence suggesting that stimulant treatment for ADHD is associated with reduced risk of subsequent substance abuse rather than sensitization to drug dependence.
Limits
The study is a non-randomized naturalistic cohort reanalysis susceptible to confounding by indication. Key details including follow-up duration, medication dosing, adherence, and exact statistical estimates are absent from the abstract.
Cited by
- supports A Harvard study found that 52% of individuals with untreated ADHD have substance abuse issues.